We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App





Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: BreathID platform offers a cost-effective clinical diagnostic solution (Photo courtesy of Meridian)
Image: BreathID platform offers a cost-effective clinical diagnostic solution (Photo courtesy of Meridian)

Meridian Bioscience Inc. (Cincinnati, OH, USA) is attending the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo where the company will exhibit its state-of-the-art urea breath test system alongside its advanced fluorescent immunoassay and molecular platforms.

At AACC 2022, Meridian will display its state-of-the-art BreathID Hp Lab urea breath test system for H. pylori detection that intuitively combines market-leading diagnostic accuracy with efficient automation and fast batch-test analysis for maximizing large lab testing throughput. The system’s built-in automated monitoring manages batch analysis, moving from test sample to test sample while noting any sample errors for post-batch handling. The BreathID platform can be used in conjunction with other Meridian H. pylori platforms for a total testing solution across the health system.

Meridian is also exhibiting the Curian fluorescent immunoassay platform focused on gastrointestinal testing that is packaged in a small footprint to improve hospital operational efficiencies. Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. Laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care.

Also on display at Meridian’s booth will be the company’s Revogene flexible molecular platform capable of single analyte and multiplex testing that is packaged in a small footprint, and can help standardize testing throughout the health system. Revogene is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. The flexible, scalable platform comes with a broad test menu for the detection of hospital inquired infections, gastrointestinal, respiratory, and neonatal diseases.
 

Related Links:
Meridian Bioscience Inc. 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
DVT/PE Test
VIDAS D-DIMER EXCLUSION II
New
Treponema Pallidum Test
ZEUS IFA Fluorescent Treponemal Antibody-Absorption (FTA-ABS) Test System

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.